NCT00761371

Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients

Exploratory Evaluation of Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients Treated With HAART (CD4+ ≥ 200 Cells mm3): An Open Labeled, Non-comparative Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: MEDA Pharma GmbH & Co. KG · Industry
• Sex: All
• Age: 18 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

Imiquimod 5% cream in the treatment of external genital or perianal warts in HIV+ patients

Detailed description

To evaluate the percentage of HIV+ subjects successfully treated with HAART, with total clearance (100%) of baseline external genital or perianal warts within 16 weeks of treatment with imiquimod 5% cream.

Conditions

• Warts

Interventions

Type	Name	Description
DRUG	Imiquimod 5% cream	Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.

Timeline

• Start date: 2002-08-01
• Primary completion: 2004-02-01
• Completion: 2004-02-01
• First posted: 2008-09-29
• Last updated: 2022-02-07

Locations

18 sites across 2 countries: Belgium, France